Wandercraft secures $75 million to accelerate AI-powered robotics and exoskeletons, with contributions from Renault Group, Bpifrance, and more.
The funding will aid in launching Eve, the first self-balancing personal exoskeleton, expanding clinical use of Atalante X, and developing humanoid robot Calvin-40.
Partnership with Renault Group enables scale-up production of exoskeletons and industrial robots like Calvin-40, for deployment in Renault factories.
Series D funding will accelerate commercialization, clinical adoption, and growth of the company's innovative robotics platforms.
Wandercraft's focus on self-balancing robotics powered by AI aims to provide independence for individuals with mobility impairments.
The company's technologies have received FDA clearances, showcased meaningful clinical improvements, and enabled over 2,500 people to rediscover mobility.
Wandercraft's dedication to expanding access to rehabilitation through AI-driven systems is exemplified by its global impact and ongoing clinical trials.
The company's showcase of Eve at global events and partnerships like with Nvidia highlight its cutting-edge technology and commitment to mobility innovation.
Wandercraft's clinical trials for Eve focus on usability and integration into daily life, welcoming participation from individuals with motor SCI.
Founded in 2012, Wandercraft leads in self-balancing walking exoskeletons, with a mission to empower individuals worldwide through innovative robotics.